Lung
cancer in practice
Reference
list
Mulatero
CW. The place of erlotinib in the NHS following NICEÕs final guidance. Lung
cancer in practice,
2008; 5.3:
6–7.
1. Giaccone G, Herbst RS, Manegold C
et al. Gefitinib
in combination with gemcitabine and cisplatin in advanced non-small-cell lung
cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22: 777–784.
2. Herbst
RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin
in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin
Oncol 2004; 22: 785-794.
3. Thatcher
N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated
patients with refractory advanced non-small-cell lung cancer: results from a
randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet 2005; 366:
1527–1537.
4. Herbst
RS, Prager D, Hermann R et al. TRIBUTE: a phase III trial of erlotinib hydrochloride
(OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced
non-small-cell lung cancer. J Clin Oncol 2005; 23: 5892–5899.
5.
Gatzemeier U, Pluzanska A, Szczesna et al. Results of a phase III trial of erlotinib (OSI-774)
combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small
cell lung cancer (NSCLC). ASCO Annual Meeting 2004; Vol 22, No 14S (July 15
Supplement) 7010.
6. Shepherd
FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med 2005; 353:
123–132.
7. http://www.nice.org.uk/nicemedia/pdf/TA162Guidance.pdf
8. http://www.nice.org.uk/nicemedia/pdf/CG024niceguideline.pdf
9. http://www.nice.org.uk/nicemedia/pdf/TA109guidance.pdf
Hayward
Medical Communications
8–10
Dryden Street
London
WC2E 9NA
Tel:
020 7240 4493
email:
edit@hayward.co.uk